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Numerous studies have documented ultrastructural abnormalities in malignant
megakaryocytes from bone marrow (BM) of myelofibrosis patients but the morphology of
these cells in spleen, an important extramedullary site in this disease, was not investigated
as yet. By transmission-electron microscopy, we compared the ultrastructural features of
megakaryocytes from BM and spleen of myelofibrosis patients and healthy controls. The
number of megakaryocytes was markedly increased in both BM and spleen. However,
while most of BM megakaryocytes are immature, those from spleen appear mature with
well-developed demarcation membrane systems (DMS) and platelet territories and are
surrounded by platelets. In BMmegakaryocytes, paucity of DMS is associated with plasma
(thick with protrusions) and nuclear (dilated with large pores) membrane abnormalities and
presence of numerous glycosomes, suggesting a skewed metabolism toward insoluble
polyglucosan accumulation. By contrast, the membranes of the megakaryocytes from the
spleen were normal but these cells show mitochondria with reduced crests, suggesting
deficient aerobic energy-metabolism. These distinctive morphological features suggest that
malignant megakaryocytes from BM and spleen express distinctive metabolic impairments
that may play different roles in the pathogenesis of myelofibrosis.
Keywords: myeloproliferative neoplasms,myelofibrosis, megakaryocytes, ultrastructural analyses, cell metabolismINTRODUCTION
Megakaryocytes are specialized cells of the bone marrow (BM) derived from committed hematopoietic
progenitor cells that become endorsed with the ability to produce platelets through a complex process of
terminal maturation defined thrombopoiesis. During maturation, megakaryocytes retain the ability to
replicate their genomic information while becoming unable to undergo cytodieresis and undergoingNovember 2020 | Volume 10 | Article 5845411
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megakaryocytes progressively increase in size and acquire nuclei
larger than normal and with poly-lobulated morphology (1, 2). In
addition, during the process of terminal maturation, the cytoplasm
of the megakaryocytes acquires distinctive ultrastructural features
described for the first time by Dr. Zucker-Franklin (1, 3). These
changes involve massive compartmentalization of the cytoplasm
into discrete regions delimited by intrusions of the plasma
membrane which forms a reticulum defined as demarcation
membrane system (DMS) delimiting areas (the pro-platelet
territories) embedded with granules containing platelet-specific
proteins, such as pro-hemostatic factors (fibrinogen, fibronectin,
von Willebrand factor), adhesion receptors (von Willebrand
factor and P-selectin), pro-angiogenic (vascular endothelial
growth factor and basic fibroblast growth factor), and anti-
angiogenic (endostatin and thrombospondin-1) growth factors
(4). On the basis of their distinctive ultrastructural morphology,
megakaryocytes are classified into four stages of maturation: the
pro-megakaryoblast (Stage 0), the megakaryoblast (Stage I), the
promegakaryocyte (Stage II), and the mature megakaryocyte
(Stage III) (Figure S1) (1). Recent evidence indicates that
mature megakaryocytes migrate toward the sinusoids where they
are stimulated by shear stresses from the blood flow and by stimuli
provided by endothelial cells to re-organize their cytoskeletal
network releasing platelets into the blood stream (5–7).
The adhesion proteins expressed by the megakaryocytes allow
their interaction with other cells. As an example, P-selectin
mediates the interaction with neutrophils that are then
engulfed within the DMS by emperipolesis. Under steady-state
conditions, neutrophils use emperipolesis to pass through the
DMS without altering the functions of the megakaryocytes (8, 9).
Inflammation, however, activates a process of pathological
emperipolesis during which neutrophils fuse their plasma
membrane with that of the DMS, releasing proteases in the
cytoplasm of the megakaryocytes. This process leads to death of
the megakaryocytes by a Tunnel-negative process defined para-
apoptosis (see Figure S1) (10, 11). By contrast with apoptosis, in
para-apoptosis chromatin does not undergo degradation but
becomes tightly condensed (12) conferring to the nuclei
distinctive heterochromatic features (13, 14).
Several morphological evidences, corroborated more recently
by molecular data, indicate that the malignant megakaryocytes
drive the progression of Philadelphia-negative myeloproliferative
neoplasms to their end stage, myelofibrosis (MF) (15). More
specifically: i) studies in mouse model with megakaryocyte
restricted expression of the driver JAK2V617F mutation (See
Table S1 for gene and protein abbreviations) demonstrate that
these cells are necessary and sufficient to induce MF (16, 17) and
ii) both in patients and mouse models, the driver mutations
induce a RSP14 ribosomopathy that reduces the GATA1 content
in megakaryocytes which is responsible for their retarded
maturation (18, 19).
The presence in BM of numerous clusters of megakaryocytes
with ultrastructural abnormalities indicating retarded maturation
was the first hallmark reported for MF (20, 21). Additional studies
indicated that the ultrastructure abnormalities are consistent withFrontiers in Oncology | www.frontiersin.org 2a block between Stage II and III (20, 22) and with engulfment by
neutrophils engaged in pathological emperipolesis which induce
their death by para-apoptosis (11, 22–25). This pathological
megakaryocyte-neutrophil interaction has been hypothesized to
be responsible for fibrosis and hematopoietic failure by increasing
the bioavailability of TGF-b in the BM microenvironment (26).
Due to BM failure and increased progenitor cell trafficking, MF
patients develop hematopoiesis in the spleen which also contains
great numbers of megakaryocytes (27). Whether, in MF, spleen
megakaryocytes express ultrastructural abnormalities similar to
those of the BM cells has not been investigated as yet. The aim of
our study is to compare the morphological abnormalities of
megakaryocytes from BM and spleen of patients with MF.MATERIAL AND METHODS
Human Subjects
Bone marrow and spleen samples were obtained from 5 and 11
MF patients, respectively for a total of 16 patients (8 females and
8 males; median age = 52.81 years, min 22 and max 70). BM and
spleens were from different patients. Post-trauma spleen from
three healthy donors (i.e. three different de-identified subjects for
each tissue type, age and sex unknown) were analyzed as control
(healthy controls, HC). The clinical features of the MF patients
included in our study are summarized in Table 1. This study was
approved by the institutional review board of Policlinico San
Matteo, Pavia, Italy (Authorization No. 20110004143, Sept 26,
2011) and is compliant with the Declaration of Helsinki for
Studies Involving Human Subjects.
Transmission-Electron Microscopy
De-calcified BM and spleen samples were fixed with 2.5%
glutaraldehyde in 0.1 cacodylate buffer, pH 7.6 (Sigma) for 2 h
at 4°C, post-fixed with osmium tetroxide (Sigma) for 60 min at
4°C, alcohol dehydrated and embedded in Spur resin (Poliscience,
Warrington, PA, USA). Semi- and ultra-thin sections were cut
with a Reichert ultramicrotome (Depew, NY, USA). Semi-thin
sections were stained with Methylene-blue. Ultra-thin sections
were assembled on 200 mesh copper grids and counterstained
with uranyl acetate and lead citrate. Morphological observations
were performed with EM 109 Zeiss (Oberkochen, Germany) and
images were acquired with AXIOSKOPE microscope (ZEISS,
Jena, Germany) equipped with a Coolsnap Videocamera. All
quantifications were done by eye examination.
Ultrastructural Identification Criteria
Megakaryocytes were identified on the basis of accepted criteria
as depicted in Figure S1 (1, 22): Megakaryoblasts (Stage I) are
cells of 15–50 mm in diameter with large, oval or kidney-shaped
nucleus and several nucleoli. The cytoplasm presents numerous
ribosomes and a well-developed rough endoplasmic reticulum
(RER); Pro-megakaryocytes (Stage II) are cells of 20–80 mm in
diameter with irregularly shaped nucleus and relatively abundant
cytop lasm conta ining a rudimenta l DMS; Mature
megakaryocytes (Stage III) are >80 mm in diameter with multi-November 2020 | Volume 10 | Article 584541
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perinuclear (with centrioles, few biosynthetically active
organelles, and many granules), an intermediate (with well-
developed DMS and pro-platelet territories) and a peripheral
(devoid of organelles and enriched of cytoskeletal proteins and
microtubules) zone (1). Pro-megakaryoblasts (Stage 0) may not
be identified on the basis of ultrastructural markers. Para-
apoptotic megakaryocytes are cells presenting megakaryocytic
features associated with a stressed cytoplasm, DMS barely
recognizable, mitochondria with broken internal crests and
highly heterochromatic nuclei (Figure S1). Plasma and nuclear
membrane abnormalities were identified on the basis of
characteristic disruptions of the electron density signal of the
lipid bilayer. Granules were identified as circular bodies
surrounded by a single membrane enclosing electron-dense
material. Polyglucosan granules and glycosomes were identified
based on published TEM criteria (Figure S2) (28–30).
Glycosomes are formed by granuli of progressively increased
electron density orderly enclosing circular areas of the cytoplasmFrontiers in Oncology | www.frontiersin.org 3that is not surrounded by membranes. Low electron-dense acid-
labile granules organize themselves as rims delimiting discrete
cytoplasmic areas, the immature glycosome. These granules are
turned by phosphorylation into heavy electron-dense acid-
insoluble polyglucosan granules which, on the basis of their
electron density, are defined as intermediate or mature
glycosomes. In the case of glycogen storage diseases, acid-
insoluble polyglucosan molecules accumulate in the cytoplasm
either as large isolated granules or as packed glycosomes (the
bodies found in Lafora disease) (30). Mitochondria are
recognized as round (cross section) or rod (longitudinal
section) structures surrounded by a double membrane system
with the inner membrane presenting regular invagination
defined crests (31).
Data Quantification and Statistical
Analyses
All evaluations were performed blind by an expert electron
microscope scientist. Megakaryocyte frequency, maturationTABLE 1 | Clinical data of the MF patients included in this study.












MF1 PMF 4 years 14.9/33.05/328
13.4/5.0/211
0 cm MF2 Int-1 Int-2 JAK2
homo
Rux 20 mg ×2
MF2 PMF 14 years 13.6/7.8/618
11.0/6.9/230
2 cm MF2 Int-1 Low MPL HU 1 g/day
MF3 pref-MF 5 years 16.7/9.74/599
15.6/8.59/597
NP MF0 Int-1 Int-1 JAK2
hetero
Phlebotomy and aspirin
MF4 pref-MF 1 year 13.4/3.5/173
14.7/4.17/137




MF5 PMF 2 years 12.7/18.1.3/322
12.5/25.1/129




MF6 PMF 4 years 11/8.6/490
5.7/11.1/22
25 cm MF2 Int-2 Low JAK 2
homo
HU 1g/day
MF7 PPV-MF 6 years NA
6.9/3.9/111
19 cm MF2 Int-1 Int-1 JAK2
homo
HU 1g/day
MF8 PPV-MF 2years 13.8/23.3/163.000
10.3/80.0/926.000
20 cm MF2 Int-1 Low JAK2V617 F
(94%)
HU 1.5 g/day
MF9 PMF 5 years 10.5/21.9/245
12.9/5.2/140
22 cm MF2 Int-2 Int-2 JAKneg MPL/
CARL unknown
HU 1g/day
MF10 pref-MF 17 years 13.8/8.5/750
8.2/6.7/155
22 cm MF0 Int-1 Low JAKneg MPL/
CARL unknown
HU 1/5g/day
MF11 PMF 6 years 11.8/11.3/574
8.0/1.75/405
14 cm MF1 Int-1 Low JAK2
hetero
HU 1g/day
MF12 PPV-MF 3 years 15.2/6.9/266.000
12.5/4.8/605.000
15 cm MF2 Int-1 Low JAK2V617 F
(23%)
HU 1.5 g/day
MF13 PMF 1 year 12.0/14.1/143
15.1/10.5/85
19 cm MF3 Int-2 Int-2 JAK2
homo
HU 2g/day
MF14 PMF 10 years NA
2.0/8.9/104.000
25 cm MF2 High NA CALR type1
(62%)
HU 1 g/day
MF15 PPV-MF 2 years 14.4/15.4/354.000
8.5/19.8/196.000
30 cm MF3 Int-2 Int-2 JAK2V617 F
(100%)
HU 1 g/day
MF16 PMF 3 months 11.8/6.2/349.000
NA
20 cm MF2 Int-2 Int-1 JAK2V617 F
(50%)
NoneNovember 2020 | VoPatients were diagnosed according to the 2016 World Health Organization (WHO) classification49. Individual patients are identified by an alphanumerical code and by a unique symbol that
was used to REPORT results obtained for individual patients in the figures (see legend of Figure 1 for further details).
PMF, primary myelofibrosis; pref-MF, prefibrotic myelofibrosis; PPV-MF, Post-Polycythemia Vera Myelofibrosis; NP, Not Palpable; Homo, homozygous; Hetero, heterozygous; Neg,
negative; HU, Hydroxyurea; Rux, Ruxolitinib.
*Red fonts: “Hb/WBC/Plt at disease onset”; green fonts: “Hb/WBC/Plt at harvest”.lume 10 | Article 584541
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were evaluated in areas of semi-thin sections corresponding to
0.19 mm2 (one semi-thin section per subject). Additional
abnormalities and their frequency were identified on individual
megakaryocytes present in thin sections, the number of
megakaryocytes analyzed per experimental group is specified in
the legend of the Figures. Results obtained with individual donors
are reported using symbol/color codes: specified for the patients
in Table 1. Symbols used for individual healthy donors are , ,
(bone marrow) and , (spleen). Results are expressed as
median, 25–75% inter-quartile range and maximum and
minimum value P-values were calculated by ANOVA using the
Origin 6.1 software (Microcal Software Inc., Northampton,
MA, USA) and differences considered statistically significant
with p < 0.05.
Pathway Analyses
Genes involved in glycogen metabolism (32) and mitochondrial
function were identified by computer searching using the
websites https://www.genecards.org/ and https://www.kegg.jp/.
The levels of their expression in microarrays of bone marrow
(BM) from myelofibrosis patients vs healthy controls (HC) are
from (33) and the original data are deposited in the Gene
Expression Omnibus database, http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE124281.Frontiers in Oncology | www.frontiersin.org 4RESULTS
BM From MF Patients Contains Great
Numbers of Mostly Immature
Megakaryocytes While the Numerous
Megakaryocytes in Their Spleen Are
Mature and Surrounded by Platelets
Semi-thin sections of both BM and spleen from MF patients
contain numbers of megakaryocytes 1.5-fold greater than those
detected in BM from HC while megakaryocytes are barely
detectable in normal spleen (Figures 1A–C). As previously
described (20, 22), megakaryocytes in BM are small and
organized in clusters (Figure 1A). Megakaryocytes are
organized in clusters also in the spleen from these patients
(Figure 1B). However, they are visibly two to three times
larger than those observed in BM, suggesting that they are
more mature.
The maturation profile of megakaryocytes from BM and
spleen of HC and MF patients is compared in Figures 2A, B.
In BM from HC, >55% of megakaryocytes are at Stage III with
fewer cells at Stage II (~30%) or I (~10%). As expected (20, 22),
in BM from MF patients, the majority of megakaryocytes are at
Stage II (~75%) and I (~25%) with very few cells (<5%) at Stage
III. By contrast, the maturation profile of megakaryocytes from
the spleen of the patients is similar to the profile observed in BMA
B
C
FIGURE 1 | The bone marrow (BM) and spleen from myelofibrosis (MF) patients contain great numbers of megakaryocytes (MKs). Representative methylene-blue
stained semi-thin sections of BM (A) and spleen (B) from MF patients and health controls (HC) (each panel a different subject). Representative megakaryocytes are
indicated by red arrows. Megakaryocytes are not detected in HC spleen (over 20 semi-thin sections from two HC analyzed). Magnification 100×. Scale bar = 5mm.
(C) Median (lines across boxes), 25–75% inter-quartile range (boxes), and maximum and minimum values (the end of the vertical line across the boxes) of the
number of megakaryocytes detected in in area of 0.19 mm2 per semi-thin sections of multiple subjects. Values obtained with individual subjects are indicated by
symbols (each subject a unique symbol, the correspondence between symbols and individual patients and HC is specified in Table 1 and Material and Methods,
respectively). *p < 0.05 with respect to BM from HC, n = number of subjects included in each experimental group.November 2020 | Volume 10 | Article 584541
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FIGURE 2 | The bone marrow (BM) from MF patients contains mostly immature megakaryocytes while megakaryocytes in MF spleen are mostly mature.
(A) Representative ultra-thin sections of Stage II megakaryocytes from BM of one healthy control (HC) and one MF patient and from a Stage III megakaryocyte from
the spleen of one additional patient. Representative megakaryocytes are presented on the left (magnification 4,400×) and detail of their cytoplasm shown on the right
to highlight the electron-density of their granules (magnification 30,000×). Light and heavy electron-dense granules are indicated by yellow and red arrows,
respectively. Scale bars = 5 and 1 mm, as indicated. (B) Frequency of megakaryocytes at different stages of maturation (as percent of viable megakaryocytes) and
(C) in para-apoptosis (as percent of total megakaryocytes) in BM and spleen from multiple MF patients and HC. *p < 0.05 with respect to the corresponding value in
HC. (D) Frequency of light electron-dense granules with respect the total number of granules detected in megakaryocytes from HC and MF patients. *p < 0.05 with
respect to the indicated experimental group. In B–C, results are presented as Median (lines across boxes), 25–75% inter-quartile range (boxes), and maximum and
minimum values (the end of the vertical line across the boxes) (for further details see legend of Figure 1). The number of subjects included in each experimental
group is indicated by n. The total number of megakaryocytes analyzed is 59 for HC BM and 215 and 430, respectively, for BM and spleen from MF patients. Results
with spleen from HC are not reported because megakaryocytes are seldom detected in this organ.Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5845415
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(~25%) or I (~10%). Some (~15%) of the megakaryocytes
detected in spleen have a clear morphology of para-apoptotic
cells while para-apoptotic megakaryocytes are barely detected in
BM (Figures 2C) which instead presented evidence of naked
para-apoptotic nuclei [ (24) and results not shown].
The retarded maturation expressed by megakaryocytes from
BM of MF patients includes the presence in the cytoplasm of
granules with light electron density, a marker for low protein
content (11, 22). To further characterize the maturation profile of
megakaryocytes in MF, the electron-density of granules of these
cells from MF BM (Stage II) and MF spleen (Stage III) was
compared to that of cells from HC BM (Stage II) (Figures 2A, D).
While the great majority of megakaryocytes from HC BM contain
high electron-dense granules, the granules of over 40% of the cells
from MF BM are light. By contrast, only ~24% of megakaryocytes
from MF spleen contain light electron-dense granules.
As a surrogate measure for the potential to undergo terminal
maturation, the relative physical localization between
megakaryocytes and platelets within the BM and spleen
architecture of MF patients and HC is compared (Figure 3). In
HC BM, numerous Stage III megakaryocytes are found at a distance
inferior of their diameter from platelets in proximity of blood
vessels. By contrast, only one Stage II megakaryocyte, out of 60 cells
analyzed, is found in proximity of platelets inMF BM. In the case of
MF spleen, however, ~50% of Stage III megakaryocytes are found
closely localized near platelets in proximity of blood vessels.
These results indicate that in MF the maturation of
megakaryocytes is halted in BM but not in spleen.Frontiers in Oncology | www.frontiersin.org 6Ultrastructural Abnormalities Unique to
Megakaryocytes From BM of MF Patients
The data described above indicate that megakaryocytes from BM
and spleen of MF patients present common (clustered
localization and poor granule content) but also distinctive
(retarded maturation in BM only) ultrastructural abnormalities.
Additional abnormalities found to be unique to megakaryocytes
from BM of MF patients are represented by alterations of the
morphological features of the plasma and nuclear membranes
(Figure 4) and by the presence of numerous glycosomes in the
cytoplasm (Figure 5). In fact, great numbers (~35%) of
megakaryocytes from MF BM present a thick plasma membrane
with numerous pseudopods that likely represent endosomes in the
process of being released from the cytoplasm (Figures 4A, C). In
addition, megakaryocytes with dilated nuclear membranes (~80% of
the cells) and abnormally large nuclear pores (~65% of the cells) are
also observed in BM from these patients (Figures 4B, D). On the
contrary, these abnormalities are seldom detected in
megakaryocytes from BM of HC and, with the exception of
pseudopods which are indeed expressed by ~30% of the cells,
they are expressed only by few (~5-20%) megakaryocytes from
MF spleen.
Interestingly enough, the cytoplasm of >30% of megakaryocytes
from BM of the patients contains oval structures surrounded by a
rim of electron-dense material enclosing areas with homogeneous
electron-density, which distinguish them from the translucent core
that instead characterizes lipid droplets (Figure 5). The electron
density and the morphological features of these structures are





FIGURE 3 | In MF spleen, megakaryocytes are frequently co-localized with platelets in the proximity of blood vessels while these cells are seldom associated with
platelets in MF BM. Representative megakaryocytes from bone marrow (BM) of two HC (A, B) and two MF (C, D), and two MF spleen (E, F). Fifty percent of
megakaryocytes from BM of HC and from spleen of MF patients are closely associated with platelets while the megakaryocyte shown in D is the only one out of 60
cells analyzed found to be associated with platelets in BM from these patients. Platelets, megakaryocytes, and blood vessels are indicated by *, arrows and
arrowheads, respectively (for further detail see legend of Figure 1). Magnification 3,000× for A, B, C, D and 4,400× for E, F. Scale bars = 2 and 1 mm, as indicated.November 2020 | Volume 10 | Article 584541
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C
D
FIGURE 4 | The membranes of megakaryocytes from BM of MF patients show unique ultrastructural abnormalities suggesting impaired membrane biosynthesis.
Details of the plasma (A) and nuclear (B) membranes of representative megakaryocytes from BM and spleen of one control (HC) and one MF patient. The plasma
membrane of megakaryocytes from MF BM appears thick and with numerous pseudopods while the nuclear membrane is dilated and with large nuclear pores. Red
arrowheads indicate thick plasma membranes, yellow and blue arrows indicate pseudopods and large nuclear pores, respectively. Nu, nucleus, Cyt, cytoplasm.
N.A., not available. Magnification 5,800× for megakaryocytes, 37,000× and 23,000× for the details of the plasma and nuclear membranes, respectively. Scale bars =
5 mm (5,800×), 1 mm (23,000×), and 0.5 mm (37,000×). (C, D) Frequency of megakaryocytes presenting ultrastructural abnormalities of plasma and nuclear
membranes with respect to the total number of viable megakaryocytes analyzed per experimental group. Results are presented as median (lines across boxes), 25–
75% inter-quartile range (boxes), and maximum and minimum values (the end of the vertical line across the boxes); see legend of Figure 1 for further detail. The
number of subjects included in each experimental group is indicated by n and the average number of megakaryocytes analyzed per group was 6 for HC BM, 35 for
MF BM, and 91 for MF spleen. *p < 0.05 with respect to the indicated value.Frontiers in Oncology | www.frontiersin.org November 2020 | Volume 10 | Article 5845417
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dense to resemble glycogen granules containing acid-insoluble
polyglucosan formed in Lafora disease (30) (Figures 5 and S2).
By contrast, these structures are observed in only 5–7% of
megakaryocytes from the patients’ spleen and are seldom detected
in cells from BM of HC (Figure 5).
Ultrastructural Abnormalities Unique to
Megakaryocytes From the Spleen of MF
Patients Include Altered Mitochondria
The number and morphology of mitochondria in megakaryocytes
fromMFBMareoverall normal compared toBMfromHC(Figure6).Frontiers in Oncology | www.frontiersin.org 8By contrast, a great number (~40%) of megakaryocytes from MF
spleen is characterized by the presence of altered mitochondria with
disorganized internal membranes and reduced crests.DISCUSSION
Our results indicate that megakaryocytes from BM and spleen
from MF patients express common but also distinctive
abnormalities. The number of patients analyzed (5 for BM and
11 for spleen) is relatively robust for TEM studies and make us
confident that these abnormalities are present in all the patients
independently from their driver mutation. Therefore, it is
conceivable that they are driven by the different supportive
microenvironment cues of the two organs. These results are in
line with recent ex-vivo data indicating that the microenvironment
profoundly affects the quality of terminal megakaryocyte
maturation (7, 35) and provide the first morphological evidence
that the microenvironment may also affect the quality of
megakaryocytes that mature in vivo.
The most striking difference observed between megakaryocytes
from BM and spleen of MF patients is the maturation profile. By
contrast with the immature morphology of megakaryocytes from
BM, the maturation profile of cells from spleen is grossly normal
with a nearly normal cellular distribution along the maturation
classes and a good proportion of cells at Stage III presenting
properly developed DMS and platelet territories. Furthermore, in
spleen, Stage III megakaryocytes are frequently localized with
platelets in proximity of blood vessels, providing circumstantial
evidence for the hypothesis that these cells are capable to
produce platelets.
It has been hypothesized that in MF megakaryocyte
maturation is halted by a RSP14 signature induced by the
driver mutations which reduces the number of ribosomes and
their ability to bind and translate GATA1 mRNA, greatly
reducing the content of this transcription factor that is
indispensable for proper lineage maturation (19, 36). The fact
that the maturation of megakaryocytes in the spleen from these
patients is normal suggested to us that additional abnormalities
cooperate with GATA1 deficiency in halting the maturation of
megakaryocytes in MF BM. This hypothesis is tested by the more
comprehensive comparison of TEM abnormalities present in
megakaryocytes from the two organs discussed below.
Terminal megakaryocyte maturation greatly increases the
cellular demand for lipids that are necessary to synthesize new
membranes in the amounts required for proper organization of
the DMS. Therefore, in addition to transcription factors, this
process is limited by lipid bioavailability. Consistent with our
previous reported that impaired cholesterol homeostasis is the
top eight hit of the expression signature of MF BM (33), our
TEM observations indicate that the membranes of
megakaryocytes from MF BM present abnormalities (thick
plasma membrane and nuclear membrane with large pores)
usually associated with poor lipid content. In addition, these
cells present in their cytoplasm numerous glycosomes,
suggesting that their glycogen metabolism is skewed towardA
B
FIGURE 5 | The cytoplasm of numerous megakaryocytes from bone marrow
(BM) of MF patients contains structures with ultrastructural features
resembling glycosomes at various stages of maturation. (A) Representative
megakaryocytes (magnification: 5,800×, scale bar = 5 mm) from the various
experimental groups with corresponding enlarged details (magnification:
37,000×, scale bar = 0.5 mm) of their cytoplasm, as indicated. The circles in
the enlarged panel of MF BM indicate glycosomes composed by granules
with the electron density characteristics of immature-acid soluble (blue) and
mature acid-insoluble (red) polyglucosan granules and of a glycosome
resembling a Lafora body (see Figure S2 for further detail). (B) Frequency, as
median (lines across boxes), 25–75% inter-quartile range (boxes), and
maximum and minimum values (the end of the vertical line across the boxes)
of megakaryocytes presenting glycogen droplets in the three groups. n =
number of subjects included in each experimental group (see legend of
Figure 1 for further detail). The number of cells analyzed per group is
reported in the legend for Figure 4. HC, healthy control; NA, not available.November 2020 | Volume 10 | Article 584541
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of lipids and glycogen, the two major storage forms of cell energy,
are tightly interrelated as demonstrated by the observation that
accumulation of glycogen in the liver elicits a positive feedback
loop involving mTORC1 that increases the expression of
lipogenic genes leading to coordinated synthesis of glycogen
and lipids (37). The fact that megakaryocytes from MF BM
contain high numbers of large, electron-dense glycosomes
suggests that these cells store great levels of glycogen in its
insoluble polyglucosan form that is not readily available for
energy homeostasis. Further support for this hypothesis comes
from a re-analyses of the expression signature of MF BM (33)
that identified modest fold changes above threshold in the
expression of several genes of the glycogen pathway, four of
which (PHKA2, PHKB, and PYGL down-regulated whereas
PRDM8 upregulated) mutated in inherited disorders associated
with increased glycogen storage (38–44) (Table S2, Figure S3).
Upregulation of PRDM8 expression is particularly intriguing
because gain of function mutations of this gene are associated
with the neurodegenerative Lafora disease (30, 41) which is
characterized by the presence in the neurons of specific
polyglucosan-rich glycosomes, defined Lafora body, similar in
morphology to some of the glycosomes identified by us in
the malignant megakaryocytes from MF BM. In conclusion, the
expression signature and the TEM observations support the
hypothesis that the glycogen pathway in megakaryocytes from
MF BM is skewed toward the formation of acid-insoluble
glycosomes, making the energy of the cells exquisitely depend
on lipid consumption and reducing the lipid pool devoted to
membrane biosynthesis.
A recent single cell expression profiling has indicated that
megakaryocytes present in BM exert distinct biological functions
as they mature (45): the most immature megakaryocytes
expression high levels of factors which regulate theFrontiers in Oncology | www.frontiersin.org 9hematopoietic stem cells, such as TGF-b and IGF1, suggesting
that these cells exert the function of negative regulators of the
hematopoietic stem cell niche. More mature megakaryocytes
express genes predicting the function of activators of the
inflammatory response (high levels of CTSS and ITGAM) and
finally only the most mature cells express genes (GPIbA, ITGB3)
necessary to produce platelets (45). According to this functional
classification, the malignant megakaryocytes in the BM of MF
patients, which are mostly at Stage I and II of maturation, are
enriched for negative regulators of the hematopoietic stem cell
niche and for promoters of inflammation, providing further
support for the hypothesis that these malignant cells drive the
hematopoietic failure in the BM (26).
Abnormalities unique to the spleen are represented by
presence of low number of morphologically “altered”
mitochondria. The fact that these abnormalities are not present
in megakaryocytes from BM is consistent with the observation
that the signature of the BM from MF patients does not contain
great alterations in genes encoding for proteins involved in
mitochondrial function (Table S3). Unfortunately, since the
expression signature of the MF spleen has not been
determined as yet, we have limited clues on the mechanisms
that induce these abnormalities in the malignant megakaryocytes
from this organ. Since the MF spleens contain great levels of
reactive oxygen species (ROS) (46), possibly produced by
mitochondria which are also susceptible to oxidative damage
(47), we suggest that increased oxidative stress is responsible for
the mitochondria abnormalities observed in the malignant cells
from this organ.
The hypothesis that lipid and energy metabolisms are
impaired in MF is consistent with a recent report indicating
that the JAK2 mutation alters lipid and glucose metabolism in
animal models of myeloproliferative neoplasms. Furthermore,
the phenotype of this model is rescued both by high fatty acidA B
FIGURE 6 | The unique ultrastructural abnormalities expressed by megakaryocytes from spleen of myelofibrotic (MF) patients include presence of altered
mitochondria with disorganized inner membrane and reduced crests. (A) Representative megakaryocyte mitochondria are indicated by white squares. Magnification
18,500×. Scale Bars = 1 mm as indicated. (B) Frequency as median (lines across boxes), 25–75% inter-quartile range (boxes), and maximum and minimum values
(the end of the vertical line across the boxes) of megakaryocytes with altered mitochondria (see legend of Figure 1 for further detail). The number of megakaryocytes
analyzed is 7 for BM from HC, 28 for BM, and 91 for spleen of MF patients. Statistically different (p < 0.01) values are indicated by *.November 2020 | Volume 10 | Article 584541
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glycolytic enzyme PFKFB3, overexpressed by malignant cells,
in combination with ruxolitinib (48). Our results refine the
conclusions of this study indicating that in MF patients’ lipid
and energy metabolism are likely skewed, respectively, in
megakaryocytes from BM and spleen. This knowledge, in turn,
suggests that high fat diet ameliorates disease manifestation by
rescuing the membrane biosynthetic defect and consequently
halting the maturation block of megakaryocytes from BM, thus
depleting this organ from the cells that drive the manifestation of
the disease.
The descriptive nature of TEM observations poses intrinsic
limitations to the mechanistic insights provided by our study.
Historically, however, TEM observations, by depicting the reality
of organ malformations, have been instrumental to drive
investigations on the pathobiology of numerous diseases,
including MF (11, 20, 22). Our results continue in this
tradition by providing information that highlights the
importance of performing additional studies to clarify the role
played by metabolic alterations of malignant megakaryocytes,
possibly induced by microenvironment cues, in the pathobiology
of MF. Ethical and technical limitations make it impossible to
perform these studies using primary megakaryocytes
prospectically isolated from BM and spleen of MF patients. In
fact, the underlying fibrosis challenges the quality of BM biopsies
from these patients that are usually small that contain number of
cells insufficient for any analyses in 50% of the cases (33). The
ethical limitation is that the symptoms of only a minority of MF
patients indicate the need for splenectomy. As a consequence,
although the study was conducted in collaboration with the two
largest MF centers in Italy, it took us more than 3 years to collect
specimens from the number of patients included in this study. It
is predicted that it will be impossible to obtain additional MF
spleen samples in the future because these symptoms are
currently treatable with ruxolitinib (49). Usually, these
challenges are addressed by analyzing as surrogate models
megakaryocytes expanded ex vivo from CD34+ cells present in
great numbers in these patients’ blood. However, the poor
fidelity existing between megakaryocyte maturation in vitro
and in vivo (7, 35) suggests that results obtained with
megakaryocytes expanded ex-vivo may not completely
reproduce the in vivo situation. Luckily megakaryocytes from
the BM and spleen of animal models, such as the Gata1low
mouse, express TEM abnormalities superimposable to those
described here for MF patients [ (36) and results not shown].
It is predicted that metabolic studies in these models will be
instrumental to clarify the effects of the organ microenvironment
on megakaryocyte maturation in MF.
In conclusion, megakaryocytes from BM and spleen of MF
patients present unique morphological alterations suggesting that
the two organs experience different metabolic abnormalities: those
from BM show glycosomes and membrane alterations suggestive of
inefficient carbohydrate and lipid metabolism while those from
spleen express mitochondria abnormalities suggesting impaired
aerobic bioenergetics. Both metabolic abnormalities represent
possible novel therapeutic targets for MF.Frontiers in Oncology | www.frontiersin.org 10DATA AVAILABILITY STATEMENT
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mutant hematopoietic cells display metabolic alterations that can be targeted
to treat myeloproliferative neoplasms. Blood (2019) 134:1832–46.
doi: 10.1182/blood.2019000162
49. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification,
and management. Am J Hematol (2016) 91:1262–71. doi: 10.1002/ajh.24592
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Zingariello, Rosti, Vannucchi, Guglielmelli, Mazzarini, Barosi,
Genova and Migliaccio. This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal is
cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.November 2020 | Volume 10 | Article 584541
